Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ivana Gojo

Showing results (111-120 of 122) with videos related to

Pageof 13
Sort By:
Blood|March 28, 2015
Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamideShannon R McCurdy, Jennifer A Kanakry, Margaret M Showel, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|December 11, 2017
Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in OncologyJeffrey Crawford, Pamela Sue Becker, James O Armitage, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 8, 2020
NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020Pamela Sue Becker, Elizabeth A Griffiths, Laura M Alwan, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 11, 2022
NCCN Guidelines® Insights: Hematopoietic Growth Factors, Version 1.2022Elizabeth A Griffiths, Vivek Roy, Laura Alwan, et al.
Transplantation and Cellular Therapy|January 1, 2023
Allogeneic Blood or Marrow Transplantation with High-Dose Post-Transplantation Cyclophosphamide for Acute Lymphoblastic Leukemia in Patients Age ≥55 YearsJonathan A Webster, Madison Reed, Hua-Ling Tsai, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 6, 2021
NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021Daniel A Pollyea, Dale Bixby, Alexander Perl, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 8, 2023
Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in OncologyDaniel A Pollyea, Jessica K Altman, Rita Assi, et al.
Blood|June 2, 2026
Ziftomenib with venetoclax and azacitidine in relapsed/refractory NPM1-mutated acute myeloid leukemiaEunice S Wang, Harry P Erba, Amer M Zeidan, et al.
Nature Medicine|March 27, 2019
Immune signature drives leukemia escape and relapse after hematopoietic cell transplantationCristina Toffalori, Laura Zito, Valentina Gambacorta, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 15, 2026
NCCN Guidelines® Insights: Acute Myeloid Leukemia, Version 3.2026Daniel A Pollyea, Jessica K Altman, Rita Assi, et al.
Pageof 13

Showing results (111-120 of 122) with videos related to

Sort By:
Pageof 13
Blood|March 28, 2015
Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamideShannon R McCurdy, Jennifer A Kanakry, Margaret M Showel, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|December 11, 2017
Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in OncologyJeffrey Crawford, Pamela Sue Becker, James O Armitage, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 8, 2020
NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020Pamela Sue Becker, Elizabeth A Griffiths, Laura M Alwan, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 11, 2022
NCCN Guidelines® Insights: Hematopoietic Growth Factors, Version 1.2022Elizabeth A Griffiths, Vivek Roy, Laura Alwan, et al.
Transplantation and Cellular Therapy|January 1, 2023
Allogeneic Blood or Marrow Transplantation with High-Dose Post-Transplantation Cyclophosphamide for Acute Lymphoblastic Leukemia in Patients Age ≥55 YearsJonathan A Webster, Madison Reed, Hua-Ling Tsai, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 6, 2021
NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021Daniel A Pollyea, Dale Bixby, Alexander Perl, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 8, 2023
Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in OncologyDaniel A Pollyea, Jessica K Altman, Rita Assi, et al.
Blood|June 2, 2026
Ziftomenib with venetoclax and azacitidine in relapsed/refractory NPM1-mutated acute myeloid leukemiaEunice S Wang, Harry P Erba, Amer M Zeidan, et al.
Nature Medicine|March 27, 2019
Immune signature drives leukemia escape and relapse after hematopoietic cell transplantationCristina Toffalori, Laura Zito, Valentina Gambacorta, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 15, 2026
NCCN Guidelines® Insights: Acute Myeloid Leukemia, Version 3.2026Daniel A Pollyea, Jessica K Altman, Rita Assi, et al.
Pageof 13